Venmax Drugs & Pharmaceuticals Ltd

Venmax Drugs & Pharmaceuticals Ltd has experienced a notable shift in its valuation parameters, with key metrics such as the price-to-earnings (P/E) and price-to-book value (P/BV) ratios moving to levels that challenge its price attractiveness. This article analyses these valuation changes in the context of historical trends, peer comparisons, and the company’s financial performance, highlighting the implications for investors amid a deteriorating quality grade and a micro-cap market capitalisation.

Venmax Drugs & Pharmaceuticals Ltd., a micro-cap pharmaceutical company with a market capitalisation of ₹30.00 crores, reported a dramatic turnaround in its Q4 FY26 results, posting a net profit of ₹0.11 crores compared to ₹0.78 crores in Q4 FY25. Whilst the company achieved remarkable revenue growth of 1,093.94% year-on-year, the headline numbers conceal troubling operational realities: operating margins remain anaemic at just 0.25%, promoter shareholding has declined sharply to 13.80%, and the stock trades at a concerning 34.35 times trailing earnings despite fundamental weaknesses. The shares gained 1.74% on May 15, 2026, trading at ₹25.70, but remain 30.47% below their 52-week high of ₹36.96.

Venmax Drugs & Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 16 Feb 2026, reflecting a reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed here are current as of 14 May 2026, providing investors with the latest perspective on the company’s position.

Venmax Drugs & Pharmaceuticals Ltd is rated 'Strong Sell' by MarketsMOJO, with this rating last updated on 16 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 30 April 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook.

Venmax Drugs & Pharmaceuticals Ltd has been downgraded from a Sell to a Strong Sell rating as of 16 Feb 2026, reflecting deteriorating technical indicators and stagnant financial performance. The company’s Mojo Score has slipped to 17.0, signalling heightened risk for investors amid a challenging market environment and weakening fundamentals.

Venmax Drugs & Pharmaceuticals Ltd has been assigned a Sell rating with a Mojo Score of 33.0, reflecting a downgrade from its previous ungraded status. This change, effective from 09 Feb 2026, is driven by deteriorating quality metrics, challenging financial trends, and a cautious technical outlook, signalling increased risk for investors in the Pharmaceuticals & Biotechnology sector.

Venmax Drugs & Pharmaceuticals Ltd has recently undergone a significant downgrade in its quality grading, shifting from a non-rated status to a below average rating as of 9 February 2026. This change reflects a reassessment of the company’s core financial health and operational consistency, raising concerns about its long-term investment appeal despite some strong sales growth. This article delves into the key financial metrics and business fundamentals that have influenced this downgrade, providing investors with a comprehensive understanding of the company’s current standing within the Pharmaceuticals & Biotechnology sector.

Venmax Drugs & Pharmaceuticals Ltd., a micro-cap pharmaceutical company with a market capitalisation of just ₹25.00 crores, posted a net profit of ₹0.03 crores in Q3 FY26 (October-December 2025), marking a sequential increase of 50.00% from Q2 FY26's ₹0.02 crores. However, this modest absolute profit figure belies deeper structural concerns that continue to plague the Hyderabad-based company, including razor-thin operating margins, negative book value, and a dramatic decline in promoter holdings that has raised serious governance questions.